CD4 and melanoma: Further supporting the importance of neoantigen-specific CD4 T-cell responses, in a personalized vaccine trial in melanoma patients, polyfunctional CD4 T cells were observed against 60% of the 97 unique neoantigens used across patients, whereas only 16% were recognized by CD8 T cells [8].